This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2014
One study found that montelukast improved respiratory disturbances in children with mild to moderate obstructive sleep apnea (OSA). No published trials regarding the use of montelukast in adults with OSA were identified. No economic evaluations or evidence-based guidelines regarding the use of montelukast for the treatment of sleep apnea were identified.
Subject indexing assigned by CRD
Acetates; Humans; Leukotriene Antagonists; Quinolines; Sleep Apnea, Obstructive
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: firstname.lastname@example.org
Date abstract record published